|
|
Vaccine Detail
|
Multipeptide XS15 Vaccine |
| Vaccine Information |
- Vaccine Name: Multipeptide XS15 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Cocktail vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor-associated HLA presented peptides (NCT04688385; NCIT_C179595)
- Immunization Route: Other
- Description: This is a vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. (NCIT_C179595) A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. (NCT04688385) A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options. (NCT05014607)
|
| Host Response |
|
|
| References |
NCIT_C179595: TLR1/2 Agonist Pam3Cys-GDPKHPKSF [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595]
NCT04688385: Personalized Multi-peptide Vaccination in CLL Patients [https://clinicaltrials.gov/study/NCT04688385]
NCT05014607: Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients (InHeVac01) [https://clinicaltrials.gov/study/NCT05014607]
|
|
